Last reviewed · How we verify
TEPOXALIN
TEPOXALIN works by inhibiting the enzyme Prostaglandin G/H synthase 2, which plays a crucial role in the production of inflammatory mediators.
TEPOXALIN is a small molecule modality targeting Prostaglandin G/H synthase 2, a key enzyme involved in inflammation. However, due to the lack of available information, its exact mechanism of action, commercial status, and approved indications are unknown. As a result, it is difficult to provide a comprehensive summary of this compound. Further research is needed to determine its potential as a therapeutic agent. Unfortunately, without more information, it is challenging to assess its safety profile and potential side effects.
At a glance
| Generic name | TEPOXALIN |
|---|---|
| Target | Prostaglandin G/H synthase 2, Arachidonate 5-lipoxygenase, Prostaglandin G/H synthase 1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Think of it like a fire: Prostaglandin G/H synthase 2 is like the fuel that keeps the fire burning. TEPOXALIN is like a fire extinguisher that helps put out the fire by reducing the amount of fuel available. By doing so, it can help reduce inflammation and alleviate symptoms associated with various conditions.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEPOXALIN CI brief — competitive landscape report
- TEPOXALIN updates RSS · CI watch RSS